


Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

| | | | |
|--|---|--|---|
| Substitute for form 1449B/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary) | | Complete if Known | |
| | | Application Number Filing Date First Named Inventor Group Art Unit Examiner Name Attorney Docket Number | 10/679,694 10/07/2003 Benjamin L. Margolis Unassigned Unassigned 034536-0839 |
| Sheet | 1 | of | 6 |



| U.S. PATENT DOCUMENTS | | | | | | |
|-----------------------|-----------------------|----------------------|-----------------------------------|---|--|---|
| Examiner Initials* | Cite No. ¹ | U.S. Patent Document | | Name of Patentee or Applicant of Cited Document | Date of Publication of Cited Document MM-DD-YYYY | Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear |
| | | Number | Kind Code ² (if known) | | | |
| ALH | A1 | 5,196,446 | | LEVITZKI et al. | 03-23-1993 | |
| ALH | A2 | 5,217,999 | | LEVITZKI et al. | 06-08-1993 | |
| ALH | A3 | 5,352,660 | | PAWSON | 10-04-1994 | |
| | | | | | | |

| NON PATENT LITERATURE DOCUMENTS | | | | | |
|---|-----------------------|--|--|--|----------------|
| Examiner Initials* | Cite No. ¹ | Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published. | | | T ⁶ |
| ALH ↓ < | | | | | |

| | | | |
|--------------------|------------------------------|------|------------|
| Examiner Signature | /Anne Holleran/ (06/19/2006) | Date | Considered |
|--------------------|------------------------------|------|------------|

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.


¹ Unique citation designation number. ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document.

⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, PO Box 1450, Alexandria, Virginia 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, PO Box 1450, Alexandria, Virginia 22313-1450.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

| | | | |
|--|---|--------------------------|----------------------|
| Substitute for form 1449B/PTO | | Complete if Known | |
| INFORMATION DISCLOSURE STATEMENT BY APPLICANT | | Application Number | 10/679,694 |
| | | Filing Date | 10/07/2003 |
| | | First Named Inventor | Benjamin L. Margolis |
| | | Group Art Unit | Unassigned |
| | | Examiner Name | Unassigned |
| (use as many sheets as necessary) | | Attorney Docket Number | 034536-0839 |
| Sheet | 2 | of | 6 |



| NON PATENT LITERATURE DOCUMENTS | | | |
|---------------------------------|-----------------------|--|----------------|
| Examiner Initials* | Cite No. ¹ | Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published. | T ⁶ |
| ALH | A13 | DOWNWARD et al., "Close Similarity of Epidermal Growth Factor Receptor and v-erb-B Oncogene Protein Sequences," <u>Nature</u> , 1984, pp. 521-527, Vol. 307 | |
| | A14 | EGAN et al., "Association of Sos Ras Exchange Protein with Grb2 is Implicated in Tyrosine Kinase Signal Transduction and Transformation," <u>Nature</u> , 1993, pp. 450-451, Vol. 363 | |
| | A15 | FISCHER et al., "Protein Tyrosine Phosphatases: A Diverse Family of Intracellular and Transmembrane Enzymes," <u>Science</u> , 1991, pp. 401-406, Vol. 253 | |
| | A16 | GAZIT et al., "Tyrophostins I: Synthesis and Biological Activity of Protein Tyrosine Kinase Inhibitors," <u>J. Medicinal Chem.</u> , 1989, pp. 2344-2354, Vol. 32 | |
| | A17 | HANKS et al., "The Protein Kinase Family: Conserved Features and Deduced Phylogeny of the Catalytic Domains," <u>Science</u> , 1988, pp. 42-52, Vol. 241 | |
| | A18 | HARDIE, "Roles of Protein Kinases and Phosphates in Signal Transduction," <u>Symp. Soc. Exp. Biol.</u> , 1990, pp. 241-255, Vol. 44 | |
| | A19 | HARLOW et al., <u>Antibodies, A Laboratory Manual</u> , Cold Spring Harbor Laboratory, 1988 (TABLE OF CONTENTS ONLY) | |
| | A20 | HASLAM et al., "Pleckstrin Domain Homology," <u>Nature</u> , 1993, pp. 309-310, Vol. 363 | |
| | A21 | HUNTER, "Cooperation Between Oncogenes," <u>Cell</u> , 1991, pp. 249-270, Vol. 64 | |
| | A22 | JONES et al., "Molecular Cloning and Identification of a Serine-Threonine Protein Kinases of the Second-Messenger Subfamily," <u>PNAS</u> , 1991, pp. 4171-4175, Vol. 88 | |
| | A23 | KING et al., "EGF Binding to its Receptor Triggers a Rapid Tyrosine Phosphorylation of the erbB-2 Protein in the Mammary Tumor Cell Line SK-BR-3," <u>EMBO J.</u> , 1988, pp. 1647-1651, Vol. 7 | |
| | A24 | KOCH et al., "SH2 and SH3 Domains: Elements That Control Interactions of Cytoplasmic Signaling Proteins", <u>Science</u> , 1992, pp. 668-674, Vol. 252 | |
| | A25 | KURY et al., "Determination of HER-2/neu Amplification and Expression in Tumor Tissue and Cultured Cells Using a Simple, Phenol Free Method for Nucleic Acid Isolation," <u>Oncogene</u> , 1990, pp. 1403-1408, Vol. 5 | |
| | A26 | LEE et al., "HER2 Cytoplasmic Domain Generates Normal Mitogenic and Transforming Signals in a Chimeric Receptor," <u>EMBO J.</u> , 1989, pp. 167-173, Vol. 8 | |
| | A27 | LI et al., "Guanine-Nucleotide-Releasing Factor hSos1 Binds to Grb2 and Links Receptor Tyrosine Kinases to Ras Signalling," <u>Nature</u> , 1993, pp. 85-88, Vol. 363 | |

| | | | |
|--------------------|------------------------------|-----------------|--|
| Examiner Signature | /Anne Holleran/ (06/19/2006) | Date Considered | |
|--------------------|------------------------------|-----------------|--|

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document.

⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, PO Box 1450, Alexandria, Virginia 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, PO Box 1450, Alexandria, Virginia 22313-1450.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

| | | | |
|---|---|-------------------------------|----------------------|
| Substitute for form 1449B/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT | | Complete if Known | |
| | | Application Number | 10/679,694 |
| (use as many sheets as necessary) | | Filing Date | 10/07/2003 |
| | | First Named Inventor | Benjamin L. Margolis |
| | | Group Art Unit | Unassigned |
| | | Examiner Name | Unassigned |
| Sheet | 3 | of | 6 |
| | | Attorney Docket Number | 034536-0839 |

| NON PATENT LITERATURE DOCUMENTS | | | |
|---------------------------------|-----------------------|--|----------------|
| Examiner Initials* | Cite No. ¹ | Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published. | T ⁶ |
| ALH | A28 | LIPPMAN et al., "The Development of Biological Therapies for Breast Cancer," <u>Science</u> , 1993, pp. 631-632, Vol. 259 | |
| | A29 | LYALL et al., "Tyrophostins Inhibit Epidermal Growth Factor (EGF)-Receptor Tyrosine Kinase Activity in Living Cells and EGF-Stimulated Cell Proliferation," <u>J. Biol. Chem.</u> , 1989, pp. 14503-14509, Vol. 264 | |
| | A30 | MARGOLIS et al., "Effect of Phospholipase C-γ Overexpression of PDGF-Induced Second Messengers and Mitogenesis," <u>Science</u> , 1990, pp. 607-610, Vol. 248 | |
| | A31 | MARGOLIS et al., "EGF Induces Tyrosine Phosphorylation of Phospholipase C-II: A Potential Mechanism for EGF Receptor Signalling," <u>Cell</u> , 1989, pp. 1101-1107, Vol. 57 | |
| | A32 | MARGOLIS et al., "High-Efficiency Expression/Cloning of Epidermal Growth Factor-Receptor-Binding Proteins with Src Homology," <u>PNAS (USA)</u> , 1992, pp. 8894-8898, Vol. 89 | |
| | A33 | MARGOLIS, "Proteins with SH2 Domains: Transducers in the Tyrosine Kinase Signalling Pathway," <u>Cell. Growth. Differ.</u> , 1992, pp. 73-80, Vol. 3 | |
| | A34 | MARGOLIS et al., <u>Int. Cell Biochem.</u> , Abstract Supplement 18B, Feb. 1994, p. 241, Abstract #1243 | |
| | A35 | MARINI et al., "The Pituitary Hormones Arginine Vasopressin-Neurophysin II and Oxytocin-Neurophysin I Show Close Linkage with Interleukin-1 on Mouse Chromosome 2", <u>Genomics</u> , 1993, pp. 200-202, Vol. 15 | |
| | A36 | MAYER et al., "A Novel Viral Oncogene with Structural Similarity to Phospholipase C," <u>Nature</u> , 1988, pp. 272-275, Vol. 332 | |
| | A37 | MAYER et al., "A Putative Modular Domain Present In Diverse Signalling Proteins," <u>Cell</u> , 1993, pp. 629-630, Vol. 73 | |
| | A38 | MAYER et al., <u>Trends in Cell. Biol.</u> , 1993, pp. 8-13, Vol. 3 | |
| | A39 | MUSACCHIO et al., "The PH Domain: A Common Piece in the Structural Patchwork of Signalling Proteins," <u>Trends in Biochem. Sci.</u> , 1993, pp. 343-348, Vol. 18 | |
| | A40 | NURSE, "Universal Control Mechanism Regulating Onset of M-phase," <u>Nature</u> , 1990, pp. 503-508, Vol. 344 | |
| | A41 | OSHEROV et al. "Selective Inhibition of the Epidermal Growth Factor and HER2/Neu Receptors by Tryphostins," <u>J. Biol. Chem.</u> , 1993, pp. 11134-11142, Vol. 268 | |
| | A42 | PADHY et al., "Identification of a Phosphoprotein Specifically Induced by the Transforming DNA of Rat Neuroblastomas," <u>Cell</u> , 1982, pp. 865-871, Vol. 28 | |

| | | |
|--------------------|------------------------------|-----------------|
| Examiner Signature | /Anne Holleran/ (06/19/2006) | Date Considered |
|--------------------|------------------------------|-----------------|


*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document.

⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, PO Box 1450, Alexandria, Virginia 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, PO Box 1450, Alexandria, Virginia 22313-1450.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

| | | | | |
|---|---|--------------------------|----------------------|---|
| Substitute for form 1449B/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT | | Complete if Known | |  |
| | | | | |
| | | Application Number | 10/679,694 | |
| | | Filing Date | 10/07/2003 | |
| | | First Named Inventor | Benjamin L. Margo is | |
| | | Group Art Unit | Unassigned | |
| | | Examiner Name | Unassigned | |
| | | Attorney Docket Number | 034536-0839 | |
| (use as many sheets as necessary) | | | | |
| Sheet | 4 | of | 6 | |

| NON PATENT LITERATURE DOCUMENTS | | | | |
|---------------------------------|-----------------------|--|--|----------------|
| Examiner Initials* | Cite No. ¹ | Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published. | | T ⁶ |
| ALH | A43 | PAWSON et al., "SH2 and SH3 Domains," <u>Current Biol.</u> , 1993, pp. 434-442, Vol. 3, No. 7 | | |
| | A44 | PAWSON et al., "SH2 and SH3 Domains: From Structure to Function," <u>Cell</u> , 1992, pp. 359-362, Vol. 71 | | |
| | A45 | PELES et al., "Cell Type Specific Interaction of Neu Differentiation Factor (HDF/hergulin) with Neu/HER-2 Suggest Complex Ligand-Receptor Relationships," <u>EMBO J.</u> , 1993, pp. 961-971, Vol. 12 | | |
| | A46 | PENDERGAST et al., "BCR Sequences Essential for Transformation by the BCR-ABL Oncogene Bind to the ABL SH2 Regulatory Domain in a Non-Phosphotyrosine-Dependent Manner," <u>Cell</u> , 1991, pp. 161-171, Vol. 66 | | |
| | A47 | PLOWMAN et al., "Heregulin Induces Tyrosine Phosphorylation of HER4/p180.sup.erbB4," <u>Nature</u> , 1993, pp. 473-475, Vol. 366 | | |
| | A48 | PLOWMAN et al., "Ligand-Specific Activation of HER4/p180.sup.erbB4, a Fourth Member of the Epidermal Growth Factor Receptor Family," <u>PNAS</u> , 1993, pp. 1746-1750, Vol. 90 | | |
| | A49 | POSADA et al., "Molecular Signal Integration. Interplay Between Serine, Threonine, and Tyrosine Phosphorylation," <u>Mol. Biol. Cell.</u> , 1992, pp. 583-592, Vol. 3 | | |
| | A50 | REN et al., "Identification of a Ten-Amino Acid Proline-Rich SH3 Binding Site," <u>Science</u> , 1993, pp. 1157-1161, Vol. 259 | | |
| | A51 | RON et al., "pGStag-A Versatile Bacterial Expression Plasmid for Enzymatic Labelling of Recombinant Proteins," <u>Biotechniques</u> , 1992, pp. 866-869, Vol. 13 | | |
| | A52 | ROZAKIS-ADCOCK et al., "Association of the Shc and Grb2/Sem5 SH2-Containing Proteins Is Implicated in Activation of the Ras Pathway by Tyrosine Kinases," <u>Nature</u> , 1992, pp. 689-692, Vol. 360 | | |
| | A53 | SADOWSKI et al., "A Noncatalytic Domain Conserved Among Cytoplasmic Protein-Tyrosine Kinases Modifies the Kinase Function and Transforming Activity of Fujinami Sarcoma Virus P130.sup.gag-fpe," <u>Mol. Cell. Biol.</u> , 1986, pp. 4396-4408, Vol. 6 | | |
| | A54 | SAP et al., "Cloning and Expression of a Widely Expressed Receptor Tyrosine Phosphatase," <u>PNAS</u> , 1990, pp. 6112-6116, Vol. 87 | | |
| | A55 | SCHECHTER et al., "The neu Oncogene: an erb-B-related Gene Encoding is 185,000-M Tumor Antigen," <u>Nature</u> , 1984, pp. 513-516, Vol. 312 | | |
| | A56 | SCHLESSINGER AND ULLRICH, "Growth Factor Signalling by Receptor Tyrosine Kinases," <u>Neuron</u> , 1992, pp. 383-397, Vol. 9 | | |

| | | | |
|--------------------|------------------------------|-----------------|--|
| Examiner Signature | /Anne Holleran/ (06/19/2006) | Date Considered | |
|--------------------|------------------------------|-----------------|--|

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.


¹ Unique citation designation number. ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document.

⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, PO Box 1450, Alexandria, Virginia 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, PO Box 1450, Alexandria, Virginia 22313-1450.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

| | | | |
|--|---|--|---|
| Substitute for form 1449B/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary) | | Complete if Known | |
| | | Application Number Filing Date First Named Inventor Group Art Unit Examiner Name Attorney Docket Number | 10/679,694 10/07/2003 Benjamin L. Margolis Unassigned Unassigned 034536-0839 |
| Sheet | 5 | of | 6 |



| NON PATENT LITERATURE DOCUMENTS | | | |
|---------------------------------|-----------------------|--|----------------|
| Examiner Initials* | Cite No. ¹ | Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published. | T ⁶ |
| ALH | A57 | SCOTT et al., "Serinine/Threonine Protein Kinases," <u>Current Opinion in Neurology</u> , 1992, pp. 289-95, Vol. 2 | |
| | A58 | SHEPARD et al., "Monoclonal Antibody Therapy of Human Cancer: Taking the HER2 Protooncogene to the Clinic," <u>J. Clin. Immunol.</u> , 1991, pp. 117-127, Vol. 11 | |
| | A59 | SKOLNICK et al., "The SH2/SH3 Domain-Containing Protein GRB2 Interacts with Tyrosine-Phosphorylated IRS1 and SHc: Implications for Insulin Control of ras Signalling," <u>EMBO J.</u> , 1993, pp. 1929-1936, Vol. 12 | |
| | A60 | SLAMON et al., "Human Breast Cancer: Correlation of Relapse and Survival with Amplification of the HER-2/neu Oncogene," <u>Science</u> , 1987, pp. 177-182, Vol. 235 | |
| | A61 | SLAMON et al., "Studies of the HER-2/neu Proto-Oncogene in Human Breast and Ovarian Cancer," <u>Science</u> , 1989, pp. 707-712, Vol. 244 | |
| | A62 | SMITH et al., "Topoisomerase II.alpha. co-amplification with erbB2 in Human Primary Breast Cancer and Breast Cancer Cell Lines: Relationship to m-AMSA and mitoxantrone Sensitivity," <u>Oncogene</u> , 1993, pp. 933-938, Vol. 8 | |
| | A63 | STAHL et al., "Sequence Similarity of Phospholipase C with the non-catalytic region of src," <u>Nature</u> , 1988, pp. 269-272, Vol. 332 | |
| | A64 | SULSTON et al., "The C. elegans Genome Sequencing Project: A Beginning," <u>Nature</u> , 1992, pp. 37-41, Vol. 356 | |
| | A65 | TANDON et al., "HER-2/neu Oncogene Protein and Prognosis in Breast Cancer," <u>J. Clin. Oncol.</u> , 1989, pp. 1120-1128, Vol. 7 | |
| | A66 | TAVASSOLI et al., "c-erbB-2/c-erbA Co-amplification Indicative of Lymph Node Metastasis, and c-myc Amplification of High Tumor Grade, in Human Breast Carcinoma," <u>British J. of Cancer</u> , 1989, pp. 505-510, Vol. 60 | |
| | A67 | TOCKMAN et al., <u>Cancer Res.</u> , 1992, pp. 2711s-2718s, Vol. 52 | |
| | A68 | TRAHEY et al., "Molecular Cloning of Two Types of GAP Complementary DNA from Human Placenta," <u>Science</u> , 1988, pp. 1697-1700, Vol. 242 | |
| | A69 | TYERS et al., "Molecular Cloning and Expression of the Major Protein Kinase C Substrate of Platelets," <u>Nature</u> , 1988, pp. 470-473, Vol. 333 | |
| ↓ | A70 | VAN de VIJER et al., "Amplification of the new (c-erbB-2) Oncogene in Human Mammary Tumors Is Relatively Frequent and Is Often Accompanied by Amplification of the Linked c-erbA Oncogene," <u>Mol. Cel. Biol.</u> , 1987, pp. 2019-2023, Vol. 7 | |

| | | |
|--------------------|------------------------------|-----------------|
| Examiner Signature | /Anne Holleran/ (06/19/2006) | Date Considered |
|--------------------|------------------------------|-----------------|

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document.

⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, PO Box 1450, Alexandria, Virginia 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, PO Box 1450, Alexandria, Virginia 22313-1450.


Substitute for form 1449B/PTO
INFORMATION DISCLOSURE
STATEMENT BY APPLICANT

(use as many sheets as necessary)

| | | | |
|-------|---|----|---|
| Sheet | 6 | of | 6 |
|-------|---|----|---|

Complete if Known

| | |
|-------------------------------|----------------------|
| Application Number | 10/679,694 |
| Filing Date | 10/07/2003 |
| First Named Inventor | Benjamin L. Margolis |
| Group Art Unit | Unassigned |
| Examiner Name | Unassigned |
| Attorney Docket Number | 034536-0839 |



NON PATENT LITERATURE DOCUMENTS

[illegible]

**Examiner
Signature**

/Anne Holleran/ (06/19/2006)

Date
Considered

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, PO Box 1450, Alexandria, Virginia 22313-1450. **DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, PO Box 1450, Alexandria, Virginia 22313-1450.**